Intersect ENT Announces Changes to its Board of Directors
Intersect ENT (Nasdaq: XENT) announced the resignation of Anthony Vernon from its Board of Directors effective March 31, 2021, after six years of service. His departure is to pursue other interests. Elisabeth Sandoval-Little has been appointed to the Board, bringing over 30 years of experience in the biopharmaceutical industry. She is expected to enhance the company's strategy and growth. Intersect ENT focuses on innovative ENT medical technologies and recently expanded its portfolio through the acquisition of Fiagon AG. This leadership change may positively influence the company's direction and market presence.
- Appointment of Elisabeth Sandoval-Little as a board member could align with growth strategies.
- Sandoval-Little's extensive experience in biopharmaceuticals may enhance strategic insights.
- Resignation of Anthony Vernon may impact continuity in Board leadership.
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Anthony Vernon has resigned from the Intersect ENT Board of Directors on March 31, 2021. Mr. Vernon has served on the Intersect ENT Board since 2015 and is resigning to pursue other interests. Subsequent to Mr. Vernon’s resignation, the Intersect ENT Board today appointed Elisabeth Sandoval-Little to the Company’s Board. Both changes are effective immediately.
“Tony has provided expert guidance to Intersect ENT and his impact fostering the growth of our company cannot be overstated,” said Thomas A. West, President and Chief Executive Officer at Intersect ENT. “On behalf of myself, the Board of Directors, and Intersect ENT’s management team, I would like to thank Tony for his dedicated and valued service to the Company.”
“We are pleased to welcome Elisabeth to the Intersect Board,” said Mr. West. “Elisabeth is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical and specialty therapeutics industries at both large market-leaders and development-stage companies. She has worked with products at all stages of the product lifecycle and her strong knowledge of the interplay between product and claims development and commercialization will be a great fit with Intersect ENT’s strategy and growth aspirations.”
“I am delighted to be joining Intersect ENT,” said Ms. Sandoval-Little. “With an established commercial presence, an expanding product base and a strong clinical program, this is an exciting time for the Company. I look forward to contributing to its future growth.”
Ms. Sandoval-Little currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately-held Alastin Skincare. Ms. Sandoval-Little previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals. She was Chief Commercial Officer for Kythera Biopharmaceuticals and spent 23 years at Allergan in a variety of commercial leadership roles of increasing responsibility. Ms. Sandoval-Little began her career in research and development at Johnson & Johnson’s Ethicon division. Ms. Sandoval-Little holds an M.B.A. from Pepperdine University and a B.S. in Biology from the University of California, Irvine.
About Intersect ENT
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.
Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc.
Forward-Looking Statements
The forward-looking statements in this press release are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. These statements and risks include: the duration and severity of the COVID-19 pandemic is unknown and could continue, and be more severe, than Intersect ENT currently expects; the unknown state of the U.S. economy following the pandemic; the level of demand for Intersect ENT’s products as the pandemic subsides; the ability of Intersect ENT to effectively and efficiently resume full commercial and manufacturing operations; and the time it will take for the economy to recover from the pandemic. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, and others which are described in the Company’s latest Form 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005409/en/
FAQ
Why did Anthony Vernon resign from Intersect ENT's Board?
What experience does Elisabeth Sandoval-Little bring to Intersect ENT?
What is the significance of the management change at Intersect ENT?
When did the changes in the Board of Intersect ENT take place?
